Satiro De Oliveira, MD

Satiro De Oliveira, MD


Assistant Professor, Department of Pediatrics
American Society of Hematology Scholar
Hyundai Hope On Wheels Scholar


English, Spanish, Portuguese


Pediatrics, Pediatric Hematology/Oncology, Pediatric Hematopoietic Stem Cell Transplantation

Institutional Affiliation

Ronald Reagan UCLA Medical Center
UCLA Medical Center, Santa Monica



Pediatric Hematology-Oncology, Childrens Hospital of Los Angeles, 2007 - 2010
Pediatric Hematology-Oncology, Boldrini Children's Center, 1999 - 2002


Internal Medicine, Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto, Brazil, 1995


MD, Faculdade de Medicina da Universidade de Sao Paulo, 1995


Pediatrics, Woodhull Medical and Mental Health Center, 2004 - 2007
Pediatrics, Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto, Brazil, 1997 - 1999

Board Certifications

Pediatric Hematology/Oncology, American Board of Pediatrics, 2011
Pediatrics, American Board of Pediatrics, 2007

Contact Information

Clinical Interests

Hematopoietic Stem Cell Transplantation, Pediatric Leukemias, Congenital Immunodeficiencies

Scientific Interests

Dr. Satiro De Oliveira has been working for many years fighting pediatric cancer, having started his career in Brazil working at a hospital exclusively dedicated to the treatment of children with cancer and blood diseases. After two years of full-time clinical work, De Oliveira realized that the cure of pediatric cancer only will come from continuous research, and decided to restart his career in the United States as a physician scientist.

Under the mentorship of Dr. Donald Kohn, De Oliveira developed protocols for gene transfer into human Hematopoietic Stem and Progenitor Cells (HSPC), in vitro differentiation of human HSPC and functional cell assays. His work has developed novel immunotherapy concepts of using modified HSPC for cancer immunotherapy.

De Oliveira's research interests are:

  1. Immunotherapy of Leukemias and Lymphomas
  2. Biology of Hematopoietic Stem Cell Transplantation
  3. Immune Reconstitution after Hematopoietic Stem Cell Transplantation and primary immune deficiencies

Highlighted Publications

Larson SM, Truscott LC, Chiou TT, Patel A, Kao R, Tu A, Tyagi T, Lu X, Elashoff D, De Oliveira SN. Pre-clinical development of gene modification of haematopoietic stem cells with chimeric antigen receptors for cancer immunotherapy. Hum Vaccin Immunother. 2017 May 4;13(5):1094-1104. doi: 10.1080/21645515.2016.1268745. Epub 2017 Jan 6.

Lowe E, Truscott LC, De Oliveira SN. In Vitro Generation of Human NK Cells Expressing Chimeric Antigen Receptor Through Differentiation of Gene-Modified Hematopoietic Stem Cells. Methods Mol Biol. 2016;1441:241-51. doi: 10.1007/978-1-4939-3684-7_20.

Larson S, De Oliveira SN. Gene-modified hematopoietic stem cells for cancer immunotherapy. Hum Vaccin Immunother. 2014;10(4):982-5. Epub 2014 Jan 9.

De Oliveira SN, Wang J, Ryan C, Morrison SL, Kohn DB, Hollis RP. A CD19/Fc fusion protein for detection of anti-CD19 chimeric antigen receptors. J Transl Med. 2013 Jan 29;11:23. doi: 10.1186/1479-5876-11-23.

De Oliveira SN, Ryan C, Giannoni F, Hardee CL, Tremcinska I, Katebian B, Wherley J, Sahaghian A, Tu A, Grogan T, Elashoff D, Cooper LJ, Hollis RP, Kohn DB. Modification of hematopoietic stem/progenitor cells with CD19-specific chimeric antigen receptors as a novel approach for cancer immunotherapy. Hum Gene Ther. 2013 Oct;24(10):824-39. doi: 10.1089/hum.2012.202.